Table 1. Selected data for chemotherapy and anti-PD1/PD-L1 in MCC.

	Chemotherapy		Nivolumab	Avelumab	Pembrolizumab
Line	1st line	2nd line	≥1st line	≥2nd line	1st line
Cohort size	62-67	20-30	22	88	25
Agent	Etoposide & platinagentb	Topotecanb	Anti PD-1	Anti PD-L1	Anti PD-1
ORR	31- 55%	9 - 23%	68%	32%	56%
9 month PFSa	15-26%	0-3%	N/Ac	33%	56%
Citations	Becker, 2017d; Cowey, 2017; Iyer, 2016;		Topalian, 2017	Kaufman, 2016	Nghiem, 2016

^aValues estimated from charts

^bmost commonly used agents

^c9 month PFS is not yet available, however 3 month median PFS is 82%

^dData for second line chemotherapy only